Browse Studies — Arctuva

Phase 1

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, t…

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Estimated

~$10 – $7,500

AstraZenecaNCT06137118

Phase 1

A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Ce…

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Estimated

~$10 – $7,500

AstraZenecaNCT07109219

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

To learn more about the long-term health in patients treated for B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Cluster of Differentiation antigen 19 (CD19) …

B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Estimated

~$10 – $750

St. Jude Children's Research HospitalNCT07048535

Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination

The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment f…

B-Cell ALLB-Cell Acute Lymphoblastic LeukaemiaB-Cell Lymphoblastic Leukemia+5 more

Estimated

~$10 – $750

Arkansas Children's Hospital Research InstituteNCT07422337